Ovid Therapeutics Inc. (OVID) — SEC Filings

Latest SEC filings for Ovid Therapeutics Inc. (OVID), explained in plain English.

Sentiment Overview: 2 bearish, 31 neutral, 2 mixed

Recent Filings (35)

• Ovid Therapeutics Inc. Files Form 4 for Ownership Changes — 4 · 2026-04-09T17:15:09-04:00 [neutral] Risk: low
  On April 9, 2026, Ovid Therapeutics Inc. filed a Form 4, reporting changes in beneficial ownership of securities. Stelios Papadopoulos, a reporting person, made
• Ovid Therapeutics Insider Jeremy Levin Files Form 4 — 4 · 2026-03-25T21:18:27-04:00 [neutral]
  This Form 4 filing indicates that Jeremy M. Levin, a reporting person for Ovid Therapeutics Inc., filed a statement of changes in beneficial ownership of securi
• 8-K Filing — 8-K · 2025-12-18T00:00:00.000Z [neutral]
• 8-K Filing — 8-K · 2025-12-11T00:00:00.000Z [neutral]
• Ovid's Q3 Loss Narrows, Cash Infusion Boosts Outlook — 10-Q · 2025-11-12T00:00:00.000Z [mixed] Risk: medium
  Ovid Therapeutics Inc. reported a net loss of $12.2 million for the three months ended September 30, 2025, and a net loss of $27.1 million for the nine months e
• Ovid Seeks 152% Stock Authorization Hike for PIPE Financing — DEF 14A · 2025-11-07T00:00:00.000Z [mixed] Risk: high
  Ovid Therapeutics Inc. is seeking stockholder approval for three critical proposals at a Special Meeting on December 11, 2025, to facilitate a significant PIPE
• Ovid Therapeutics Files 8-K on Agreements and Equity Sales — 8-K · 2025-10-03T00:00:00.000Z [neutral] Risk: medium
  Ovid Therapeutics Inc. filed an 8-K on October 3, 2025, reporting on several events as of October 2, 2025. These include entering into a material definitive agr
• Ovid Therapeutics Files 8-K Current Report — 8-K · 2025-09-16T00:00:00.000Z [neutral] Risk: low
  Ovid Therapeutics Inc. filed an 8-K on September 16, 2025, reporting an event on September 11, 2025. The filing is a current report under Section 13 or 15(d) of
• Ovid Therapeutics Faces Going Concern Doubt Amidst Widening Losses — 10-Q · 2025-08-13T00:00:00.000Z [bearish] Risk: high
  Ovid Therapeutics Inc. reported a net loss of $4.7 million for the three months ended June 30, 2025, a significant decline from the net income of $8.5 million i
• Ovid Therapeutics Files 8-K on Security Holder Matters — 8-K · 2025-07-10T00:00:00.000Z [neutral] Risk: low
  Ovid Therapeutics Inc. filed an 8-K on July 10, 2025, reporting on the submission of matters to a vote of security holders. The filing details events that occur
• Ovid Therapeutics Files 8-K — 8-K · 2025-06-25T00:00:00.000Z [neutral] Risk: low
  Ovid Therapeutics Inc. filed an 8-K on June 25, 2025, reporting an event under "Other Events." The filing details the company's corporate information, including
• Ovid Therapeutics Details 2024 Executive Equity Compensation — DEF 14A · 2025-05-22T00:00:00.000Z [neutral] Risk: low
  Ovid Therapeutics Inc.'s DEF 14A filing, dated May 22, 2025, primarily details executive compensation and equity award information for the fiscal year ended Dec
• Ovid Therapeutics Files Q1 2025 10-Q — 10-Q · 2025-05-13T00:00:00.000Z [neutral] Risk: low
  Ovid Therapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information for the first quarter of 2025, including co
• Ovid Therapeutics Files 8-K on Shareholder Nominations — 8-K · 2025-05-02T00:00:00.000Z [neutral] Risk: low
  Ovid Therapeutics Inc. filed an 8-K on May 2, 2025, reporting on shareholder nominations pursuant to Exchange Act Rule 14a-11. The filing indicates that the com
• Ovid Therapeutics Files 2024 Annual Report Amendment — 10-K/A · 2025-04-30T00:00:00.000Z [neutral] Risk: low
  Ovid Therapeutics Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. This amendment, filed on April 30, 2025, pr
• 10-K Filing — 10-K · 2025-03-11T00:00:00.000Z [neutral]
• Ovid Therapeutics Announces Executive and Director Appointments — 8-K · 2025-03-05T00:00:00.000Z [neutral] Risk: low
  Ovid Therapeutics Inc. announced on March 1, 2025, changes in its executive and director roles. Dr. Amit Patel has been appointed as Chief Medical Officer, and
• Ovid Therapeutics Faces Delisting Concerns — 8-K · 2025-02-13T00:00:00.000Z [bearish] Risk: high
  Ovid Therapeutics Inc. filed an 8-K on February 13, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The earlie
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• Ovid Therapeutics Files Q3 2024 10-Q — 10-Q · 2024-11-12T00:00:00.000Z [neutral] Risk: medium
  Ovid Therapeutics Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and operational updates. Specific fin
• Ovid Therapeutics Relocates Principal Executive Offices — 8-K · 2024-09-11T00:00:00.000Z [neutral] Risk: low
  Ovid Therapeutics Inc. announced on September 8, 2024, a change in its principal executive offices to 441 Ninth Avenue, 14th Floor, New York, NY 10001. The comp
• Ovid Therapeutics Files Q2 2024 10-Q — 10-Q · 2024-08-13T00:00:00.000Z [neutral] Risk: medium
  Ovid Therapeutics Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business opera
• Ovid Therapeutics Appoints New CEO — 8-K · 2024-08-02T00:00:00.000Z [neutral] Risk: medium
  Ovid Therapeutics Inc. announced on July 30, 2024, a change in its board of directors. Dr. Jeremy Levin has been appointed as the new Chief Executive Officer an
• Ovid Therapeutics Files 8-K — 8-K · 2024-07-01T00:00:00.000Z [neutral] Risk: low
  Ovid Therapeutics Inc. filed an 8-K on July 1, 2024, to report other events. The filing does not contain specific details about the nature of these events, doll
• Ovid Therapeutics Appoints New CEO, Dr. Amit Patel — 8-K · 2024-06-28T00:00:00.000Z [neutral] Risk: medium
  Ovid Therapeutics Inc. announced on June 27, 2024, that its Board of Directors has appointed Dr. Amit Patel as Chief Executive Officer, effective immediately. D
• Ovid Therapeutics Files 8-K — 8-K · 2024-06-17T00:00:00.000Z [neutral] Risk: low
  Ovid Therapeutics Inc. filed an 8-K on June 17, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain
• Ovid Therapeutics Files 8-K on Shareholder Vote — 8-K · 2024-06-07T00:00:00.000Z [neutral] Risk: low
  Ovid Therapeutics Inc. filed an 8-K on June 7, 2024, reporting on a matter submitted to a vote of security holders on June 6, 2024. The filing details the compa
• Ovid Therapeutics Files Q1 2024 Report — 10-Q · 2024-05-14T00:00:00.000Z [neutral] Risk: medium
  Ovid Therapeutics Inc. filed its quarterly report for the period ended March 31, 2024. The company is registered in Delaware and its common stock trades on the
• Ovid Therapeutics Inc. Files Definitive Proxy Statement — DEF 14A · 2024-04-24T00:00:00.000Z [neutral] Risk: low
  Ovid Therapeutics Inc. (OVID) filed a Proxy Statement (DEF 14A) with the SEC on April 24, 2024. Ovid Therapeutics Inc. filed a Definitive Proxy Statement (DEF 1
• Ovid Therapeutics Inc. Files 2023 Annual Report on Form 10-K — 10-K · 2024-03-08T00:00:00.000Z [neutral] Risk: medium
  Ovid Therapeutics Inc. (OVID) filed a Annual Report (10-K) with the SEC on March 8, 2024. Ovid Therapeutics Inc. filed its 2023 Form 10-K on March 8, 2024. The
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• Rubric Capital Management LP Holds 5.3M Ovid Therapeutics Shares — SC 13G/A · 2024-02-12T00:00:00.000Z [neutral] Risk: low
  Rubric Capital Management LP, a Delaware-based investment firm, filed an amended SC 13G/A on February 12, 2024, disclosing its ownership of 5,315,969 shares of
• BlackRock Discloses Passive Stake in Ovid Therapeutics — SC 13G · 2024-01-29T00:00:00.000Z [neutral]
  BlackRock Inc., a massive investment firm, has filed an SC 13G indicating its ownership in Ovid Therapeutics Inc. as of December 31, 2023. This filing, made und